Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics enrols 250 for grass pollen allergy trial

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients.
Allergy Therapeutics enrols 250 for grass pollen allergy trial
Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has enrolled 250 patients into a Phase IIb study in the US for a new injectable treatment for grass pollen sufferers.

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients with headline data expected at the end of the first half of 2016. The results of that should lead on to a US Phase III study.

Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks, avoiding the continuous administration required by conventional subcutaneous injectable treatments.

For the first time, the dosing study will use two mobile environmental exposure chambers.

Based in Cincinnati and in New Jersey Shore, the chambers are inflatable laboratories that enable subjects to be exposed to a constant concentration of pollen for periods of three hours over four consecutive days. These labs will allow the study to be conducted outside of the grass pollen season.

Tim Higenbottam, Allergy‘s R&D director said the trial was on schedule and would prepare the ground for entry into the high value US market.

“GrassMATAMPL has the potential to become the best in class ultra-short course SCIT [injectable] in the US market”

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Related Articles

blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
stem-cells.jpg
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.